HHS Terminates Moderna’s $766 Million in mRNA Bird Flu Injection Contracts

1 month_ago 20

NE LAISSER PAS LE 5G DETRUIRE VOTRE ADN Protéger toute votre famille avec les appareils Quantiques Orgo-Life®

Publicité par Adpathway

Termination of both development and purchase contracts signals a major shift away from the failed mRNA platform.

According to Reuters, the U.S. Department of Health and Human Services (HHS) has canceled two major contracts worth $766 million with Moderna for its experimental mRNA H5N1 bird flu injections—terminating both late-stage development funding and any government purchase commitments.

The terminated contracts include:

$590 million awarded in January 2025 under the Biden administration for expanded late-stage clinical trials
$176 million awarded in 2024 to support early development of Moderna’s mRNA flu platform

While Moderna announced “positive interim data,” HHS pulled the plug—marking a major policy shift away from dangerous mRNA injection programs.

This is a very positive development. mRNA-based injections have repeatedly shown complete failure and cause catastrophic harm, as we’ve seen with COVID-19 and RSV.

Click the share button below to email/forward this article. Follow us on Instagram and X and subscribe to our Telegram Channel. Feel free to repost Global Research articles with proper attribution.

Nicolas Hulscher, MPH, Epidemiologist and Foundation Administrator, McCullough Foundation

Global Research is a reader-funded media. We do not accept any funding from corporations or governments. Help us stay afloat. Click the image below to make a one-time or recurring donation.

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: [email protected]

www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: [email protected]

read-entire-article